Cipher Pharmaceuticals first-quarter total revenue up 52 percent Cipher Pharmaceuticals Inc.
Cipher Pharmaceuticals’ first-quarter total revenue up 52 percent Cipher Pharmaceuticals Inc. today announced its financial and operational outcomes for the three months ended March 31, 2010 precio Kamagra soft .9 million, powered by growth of Lipofen prescriptions. – Net reduction narrowed to $0.5 million, or $0.02 per share, compared with a loss of $0.8 million, or $0.03 per share, in Q1 2009. – Reached enrolment mid-point of CIP-ISOTRETINOIN Phase III safety trial. – Received favourable overview judgement movement for CIP-TRAMADOL ER, lifting 30-month stay of approval. – New Drug Submission for CIP-TRAMADOL ER recognized for review by Wellness Canada.
Civil action against BioAlliance Pharma gets rejected BioAlliance Pharma SA announces today that the American District Judge offers granted the movement to dismiss of BioAlliance Pharma and among its executive in response to the civil action filed by Eurofins. Eurofins filed an appeal. In 2008, Eurofins Pharma US Keeping Inc. Furthermore, BioAlliance Pharma instituted legal proceedings against Eurofins in Paris in January 2009 for non-development of the technology and harm of its picture. BioAlliance was advised by Ron Soffer, Lawyer, Member of the Paris Bar.